CytoDyn Inc.
CYDY
$0.25
-$0.01-2.40%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.87M | 7.37M | 7.27M | 8.48M | 9.73M |
| Depreciation & Amortization | -9.00K | -9.00K | -9.00K | -20.00K | -18.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.12M | 17.72M | 15.32M | 16.89M | 16.30M |
| Operating Income | -19.12M | -17.72M | -15.32M | -16.89M | -16.30M |
| Income Before Tax | -38.86M | -21.02M | 3.75M | -7.09M | -14.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.86 | -21.02 | 3.75 | -7.09 | -14.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.86M | -21.02M | 3.75M | -7.09M | -14.25M |
| EBIT | -19.12M | -17.72M | -15.32M | -16.89M | -16.30M |
| EBITDA | -19.10M | -17.70M | -15.31M | -16.87M | -16.28M |
| EPS Basic | -0.03 | -0.02 | 0.00 | -0.01 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.04 | -0.02 | 0.00 | -0.01 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 4.98B | 4.94B | 4.82B | 4.60B | 4.35B |
| Average Diluted Shares Outstanding | 4.98B | 4.94B | 4.89B | 4.66B | 4.42B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |